Theoretical Studies on Azaindoles as Human Aurora B Kinase Inhibitors: Docking, Pharmacophore and ADMET Studies

  • Rajashekar Vadlakonda
  • Raghunandan Nerella
  • Sreenivas Enaganti
Original Research Article

Abstract

Aurora kinases are the cell cycle mitotic regulators processing multiple functions during cell division. Altered mechanism of these mitotic kinases may contribute to genomic instability that is most often correlated with tumorigenesis, which has been reported in many human cancers. Selective blockage of the aberrantly expressed Aurora kinases has the potential therapeutic assessment to control the deregulated cell cycle machinery and their associated risks of cancer. Using a combination of docking-, ligand- and structure-based pharmacophore strategies, in the present study, we have tried to predict the anticancer potentiality of our synthesized compounds (A1 to A5 and B1 to B9) against human Aurora B kinase. The results revealed that among all the compounds, compound B7 may act as a best candidate to be an agent of the high binding affinity with a score of 113.464 kcal/mol and good pharmacophoric features with acceptable fit values of both ligand- and structure-based pharmacophore models. Consequently, ADMET properties are also calculated to predict the safer efficacy of the compounds.

Keywords

Aurora kinases Cancer Cell cycle Docking Genomic stability Pharmacophore 

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F( (2013) GLOBOCAN 2012 v1.0 cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, LyonGoogle Scholar
  2. 2.
    Dikmen M, Ozturk N, Ozturk Y (2011) The antioxidant potency of Punica granatum L. fruit peel reduces cell proliferation and induces apoptosis on breast cancer. J Med Food 14:1638–1646CrossRefPubMedGoogle Scholar
  3. 3.
    Shen Z (2011) Genomic instability and cancer: an introduction. J Mol Cell Biol 3(1):1–3CrossRefPubMedGoogle Scholar
  4. 4.
    Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:220–228CrossRefPubMedGoogle Scholar
  5. 5.
    Failes TW, Mitic G, Abdel-Halim H, Po’uha ST, Liu M, Hibbs DE, Kavallaris M (2012) Evolution of resistance to Aurora Kinase B inhibitors in leukaemia cells. PLoS ONE 7(2):30734CrossRefGoogle Scholar
  6. 6.
    Bayliss R, Fry A, Haq T, Yeoh S (2012) On the molecular mechanisms of mitotic kinase activation. Open Biol 2:120136CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Jayanthan A, Ruan Y, Truong TH, Narendran A (2014) Aurora Kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. PLoS ONE 9(7):102741CrossRefGoogle Scholar
  8. 8.
    Brognard J, Hunter T (2011) Protein kinase signaling networks in cancer. Curr Opin Genet Dev 21:4–11CrossRefPubMedGoogle Scholar
  9. 9.
    Chan KS, Koh CG, Li HY (2012) Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 3(10):411CrossRefGoogle Scholar
  10. 10.
    Lin ZZ, Chou CH, Cheng AL, Liu WL, Chia-Hsien Cheng J (2014) Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. Int J Cancer 135:492–501CrossRefPubMedGoogle Scholar
  11. 11.
    Hochegger H, He´garat N, Pereira-Leal JB (2013) Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol 3:120185CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Aurora kinase inhibitors–rising stars in cancer therapeutics? Mol Cancer Ther 9:268–278CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lens SMA, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10:825–841CrossRefPubMedGoogle Scholar
  14. 14.
    Kamaraj B, Kumar A, Purohit R (2013) Evolutionary reconstruction and population genetics analysis of aurora kinases. PLoS ONE 8(9):757–763CrossRefGoogle Scholar
  15. 15.
    Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA (2013) Aurora-A kinase (AURKA) in normal and pathological cell growth. Cell Mol Life Sci 70(4):661–687CrossRefPubMedGoogle Scholar
  16. 16.
    Carmena M, Wheelock M, Funabiki H, Earnshaw WC (2012) The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol 13:789–803CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Vander Waal MS, Hengeveld RC, Vander Horst A, Lens SM (2012) Cell division control by the chromosomal passenger complex. Exp Cell Res 318(12):1407–1420CrossRefGoogle Scholar
  18. 18.
    Neaz MM, Muddassar M, Pasha FA, Cho SJ (2010) Structural studies of B-type Aurora kinase inhibitors using computational methods. Acta Pharmacol Sin 31(2):244–258CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Avo Santos M, van de Werken C, de Vries M, Jahr H, Vromans MJ, Laven JS, Fauser BC, Kops GJ, Lens SM, Baart EB (2011) A role for Aurora C in the chromosomal passenger complex during human preimplantation embryo development. Hum Reprod 26:1868–1881CrossRefPubMedGoogle Scholar
  20. 20.
    Linardopoulos S, Blagg J (2015) Aurora Kinase inhibition: a new light in the sky? J Med Chem 58(13):5186–5188CrossRefPubMedGoogle Scholar
  21. 21.
    Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA (2013) The role and targeting of Aurora kinases in head and neck cancer. Lancet Oncol 14(10):e425–e435CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Moore AS, Blagg J, Linardopoulos S, Pearson ADJ (2010) Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 24:671–678CrossRefPubMedGoogle Scholar
  23. 23.
    Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM (2011) High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res 35:260–264CrossRefPubMedGoogle Scholar
  24. 24.
    Lampson MA, Cheeseman IM (2011) Sensing centromere tension: aurora B and the regulation of kinetochore function. Trends Cell Biol 21(3):133–140CrossRefPubMedGoogle Scholar
  25. 25.
    Katayama H, Sen S (2010) Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 1799:829–839CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    An Ying, Lee Eun, Yeongji Yu, Yun Jieun, Lee Myeong Youl, Kang Jong Soon, Kim Woo-Young, Jeon Raok (2016) Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors. Bioorg Med Chem Lett 26(13):3067–3072CrossRefPubMedGoogle Scholar
  27. 27.
    Batool S, Ferdous S, Kamal MA, Iftikhar H, Rashid S (2013) In silico screening for identification of novel Aurora Kinase inhibitors by molecular docking, dynamics simulations and ligand-based hypothesis approaches. Enzyme Eng 2:106Google Scholar
  28. 28.
    Karthigeyan D, Surabhi S, Mizar P, Soumik S, Banerjee A, Sinha SH, Dasgupta D, Narayana C, Kundu TK (2016) A dual non-ATP analogue inhibitor of Aurora Kinases A and B, derived from resorcinol with a mixed mode of inhibition. Chem Biol Drug Des 87:958–967CrossRefPubMedGoogle Scholar
  29. 29.
    Petsalaki Eleni, Zachos George (2016) Clks 1,2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint. Nat Commun 7:11451CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sasai K, Katayama H, Hawke DH, Sen S (2015) Aurora-C interactions with Survivin and INCENP Reveal shared and distinct features compared with Aurora B chromosome passenger protein complex. PLoSONE 11(6):e0157305CrossRefGoogle Scholar
  31. 31.
    Kumar A, Purohit R (2014) Use of long term molecular dynamics simulation in predicting cancer associated SNPs. PLoS Comput Biol 10(4):E1003318CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Association of Scientists in the Interdisciplinary Areas and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Rajashekar Vadlakonda
    • 1
  • Raghunandan Nerella
    • 2
  • Sreenivas Enaganti
    • 3
  1. 1.Department of Pharmaceutical ChemistryVikas College of PharmacyJangaon, WarangalIndia
  2. 2.Department of Pharmaceutical ChemistryBalaji Institute of Pharmaceutical SciencesLaknepally, Narsampet, WarangalIndia
  3. 3.Department of BioinformaticsAverinbiotechHyderabadIndia

Personalised recommendations